| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/04/2015 | EP2842561A1 Enteral environment-improving agent |
| 03/04/2015 | EP2842560A1 Composition for promoting bifidobacteria growth |
| 03/04/2015 | EP2842559A2 Compounds, compositions and methods for the treatment of viral infections and other medical disorders |
| 03/04/2015 | EP2842558A1 Cgrp responsiveness promoter |
| 03/04/2015 | EP2842557A1 Mildronate in ophthalmic disorders |
| 03/04/2015 | EP2842556A2 Alpha-derivatives of cis-monounsaturated fatty acids for use as medicines |
| 03/04/2015 | EP2842555A2 Alpha-derivatives of cis-monounsaturated fatty acids for use as medicines in the treatment of diabetes |
| 03/04/2015 | EP2842554A1 Broncholytic drug on the basis of prostaglandin |
| 03/04/2015 | EP2842553A1 Analgesic |
| 03/04/2015 | EP2842552A1 Cinacalcet and neuroblastic tumours |
| 03/04/2015 | EP2842551A1 Complementary personal lubricant compositions |
| 03/04/2015 | EP2842550A1 Compositions comprising sponge collagen with a defined in vivo release profile, especially in the colon, their preparation and use |
| 03/04/2015 | EP2842549A1 Orally disintegrating tablet and method for producing same |
| 03/04/2015 | EP2842548A1 Polymeric synthetic antidote |
| 03/04/2015 | EP2842547A1 Improved fenofibrate compositions |
| 03/04/2015 | EP2842546A1 Unit structure-type pharmaceutical composition for nucleic acid delivery |
| 03/04/2015 | EP2842428A1 Oral composition |
| 03/04/2015 | EP2842424A1 Methods and compositions for the generation of peracetic acid on site at the point-of-use. |
| 03/04/2015 | EP2842423A1 Methods and compositions for the generation of peracetic acid on site at the point-of-use. |
| 03/04/2015 | EP2841939A1 Method for detoxification or measurement of at least one compound or at least one fluid in a host body |
| 03/04/2015 | EP2841604A1 Assays, methods and apparatus for assessing rna disruption |
| 03/04/2015 | EP2841580A2 Wound treatment |
| 03/04/2015 | EP2841579A1 Microrna compounds and methods for modulating mir-21 activity |
| 03/04/2015 | EP2841578A1 RNA modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders |
| 03/04/2015 | EP2841577A1 HIGH COMPLEXITY siRNA POOLS |
| 03/04/2015 | EP2841445A1 2.2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
| 03/04/2015 | EP2841444A1 Process for preparation of 17-substituted steroids |
| 03/04/2015 | EP2841438A1 Pantothenate derivatives for the treatment of neurologic disorders |
| 03/04/2015 | EP2841437A1 Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation |
| 03/04/2015 | EP2841435A1 Pyrrolopyridinone derivatives as ttx-s blockers |
| 03/04/2015 | EP2841434A1 Process for manufacturing naphthyridine derivatives |
| 03/04/2015 | EP2841432A1 Tetrahydropyran dgat1 inhibitors |
| 03/04/2015 | EP2841431A1 Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same |
| 03/04/2015 | EP2841426A1 Antibacterial quinoline derivatives |
| 03/04/2015 | EP2841425A1 Antibacterial quinoline derivatives |
| 03/04/2015 | EP2841421A1 Amide derivatives as ttx-s blockers |
| 03/04/2015 | EP2841419A1 Crystalline forms of saxagliptin |
| 03/04/2015 | EP2841418A1 (3,4-dichloro-phenyl)-((s)-3-propyl-pyrrolidin-3-yl)-methanone hydrochloride and manufacturing processes |
| 03/04/2015 | EP2841417A1 Synthesis of lactams |
| 03/04/2015 | EP2841416A1 Novel compounds |
| 03/04/2015 | EP2841409A1 Compounds for use as inhibitors of alternative oxidase or cytochrome bc1 complex |
| 03/04/2015 | EP2841107A1 Cytotoxic-drug delivering molecules targeting hiv (cdm-hs), cytotoxic activity against the human immunodeficiency virus and methods of use |
| 03/04/2015 | EP2841104A1 Prostaglandin and vasoconstrictor pharmaceutical compositions and methods of use |
| 03/04/2015 | EP2841099A1 Combination of cd37 antibodies with bendamustine |
| 03/04/2015 | EP2841092A1 Methods, compounds and compositions for treatment of parainfluenza virus in immunocompromised patients |
| 03/04/2015 | EP2841084A1 Peptides and use thereof in the treatment of large cell lung cancer |
| 03/04/2015 | EP2841078A1 Polymer-based dialysate |
| 03/04/2015 | EP2841077A1 Dietary fiber compositions for the treatment of metabolic disease |
| 03/04/2015 | EP2841076A1 Methods for increasing swallowing efficacy |
| 03/04/2015 | EP2841075A1 Agents and methods for treating and preventing seborrheic keratosis |
| 03/04/2015 | EP2841074A1 Intrauterine application of 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one systems, intrauterine systems containing 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one, as well as the use thereof in contraception and gynaecological therapy |
| 03/04/2015 | EP2841073A1 Application of 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one systems in the treatment of menorrhagia, as well as intrauterine systems containing 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one for treating uterine bleeding disorders |
| 03/04/2015 | EP2841072A1 Combination meloxicam and xylazine therapy in animals |
| 03/04/2015 | EP2841071A1 Formulations and methods for delaying onset of chronic neuropathic pain |
| 03/04/2015 | EP2841070A2 Design and synthesis of novel inhibitors of isoprenoid biosynthesis |
| 03/04/2015 | EP2841069A1 Highly pure pyrroloquinolinyl-pyrrole-2,5-dione and pyrroloquinolinyl-pyrrolidine-2,5-dione and methods of preparing same |
| 03/04/2015 | EP2841068A2 Crhr1 antagonists for use in the treatment of patients having crh overactivity |
| 03/04/2015 | EP2841066A1 Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
| 03/04/2015 | EP2841065A1 Method for treating irritable bowel syndrome with diarrhea |
| 03/04/2015 | EP2841064A1 Use of n-acetylcysteine amide in the treatment of disease and injury |
| 03/04/2015 | EP2841063A2 Compositions and methods for treating ptsd and related diseases |
| 03/04/2015 | EP2841062A1 Methods and compositions for raf kinase mediated diseases |
| 03/04/2015 | EP2841061A1 Methods for treating cardiovascular disorder |
| 03/04/2015 | EP2841060A1 Method of prevention of neurological diseases |
| 03/04/2015 | EP2841058A1 Delazed release pharmaceutical compositions of salsalate |
| 03/04/2015 | EP2841054A1 Injectable preparation |
| 03/04/2015 | EP2841053A1 Treatment method for steroid responsive dermatoses |
| 03/04/2015 | EP2841051A1 Use of dicyclohexylmethanol derivatives with anti-microbial properties |
| 03/04/2015 | EP2840906A1 Association of beta-glucans and arabinoxylans |
| 03/03/2015 | US8969654 Triterpene oxidase derived from plant belonging to genus Glychyrrhiza, gene encoding the triterpene oxidase, and use of the protein or the gene |
| 03/03/2015 | US8969622 Dendritic molecular intracellular transporters and methods of making and using same |
| 03/03/2015 | US8969617 18β-Glycyrrhetinic acid derivatives and synthetic method thereof |
| 03/03/2015 | US8969588 Solid forms of an antiviral compound |
| 03/03/2015 | US8969587 RAF kinase modulator compounds and methods of use thereof |
| 03/03/2015 | US8969584 PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof |
| 03/03/2015 | US8969583 3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivatives as kinase inhibitors |
| 03/03/2015 | US8969578 Inhibitors of STAT3 |
| 03/03/2015 | US8969576 Substituted N-aryl pyridinones |
| 03/03/2015 | US8969575 Substituted N-Aryl pyridinones |
| 03/03/2015 | US8969574 Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| 03/03/2015 | US8969573 Compounds for the inhibition of cellular proliferation |
| 03/03/2015 | US8969571 Biphenyl derivatives |
| 03/03/2015 | US8969570 Beta-lactamase inhibitors |
| 03/03/2015 | US8969569 Salt and crystalline forms thereof of a drug |
| 03/03/2015 | US8969565 Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use |
| 03/03/2015 | US8969564 Aryl ether-base kinase inhibitors |
| 03/03/2015 | US8969557 ACC inhibitors and uses thereof |
| 03/03/2015 | US8969556 Purine-based triazoles |
| 03/03/2015 | US8969548 Antioxidant small molecules aimed at targeting metal-based oxidative stress in neurodegenerative disorders |
| 03/03/2015 | US8969544 Combined use of PRAME inhibitors and HDAC inhibitors |
| 03/03/2015 | US8969515 Pharmaceutical composition for treating hyperproliferative diseases |
| 03/03/2015 | US8969420 Treatment of pervasive developmental disorders with redox-active therapeutics |
| 03/03/2015 | US8969419 Animal feed compositions and feeding methods |
| 03/03/2015 | US8969418 Active substance combination of licochalcone A and phenoxyethanol |
| 03/03/2015 | US8969417 Pharmaceutical compositions for treatment of Parkinsons disease |
| 03/03/2015 | US8969416 Polyvinylpyrrolidone-containing acetaminophen liquid formulations |
| 03/03/2015 | US8969415 Intraocular drug delivery systems |
| 03/03/2015 | US8969414 Intrathecal baclofen pharmaceutical dosage forms with fewer degradation products |
| 03/03/2015 | US8969413 Methods of using (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid |
| 03/03/2015 | US8969412 Use for a composition comprising chloroprocaine HCL, a new composition comprising chloroprocaine HCL and a method for its manufacture |